The administration of vemurafenib was interrupted until the resolution of the toxic impact to at least grade 1 and restarted at 720 mg two times daily , with a dosage decrease to 480 mg twice daily if the toxic effects recurred. If the toxic impact did not improve to grade 1 or recurred or lower at the 480-mg twice-daily dose, treatment was discontinued permanently. The administration of dacarbazine was interrupted for grade three or four 4 toxic effects and could be restarted on recovery within a week to grade 1 or quality 2 or at 75 percent dosage for grade 4 neutropenia or febrile neutropenia. A second dose decrease was allowed, if required. Antiemetics and granulocyte colony-stimulating factor were administered according to specifications at each study middle. Treatment was discontinued on disease progression unless ongoing treatment was in the very best interest of the individual in the judgment of the investigator and the sponsor.During his tenure as NCPA president from 2000 to 2001, Carson established the Special Committee on Technology and Creativity. NCPA also applauded Carson’s efforts to teach pharmacists on how to provide pharmacist treatment services. Carson is a past president and former table member of the Texas Pharmacy Association. John W. Dargavel Medal for Leadership, Program: James H. Vincent NCPA awarded the second medal to James H. Vincent posthumously, with his child Matt Vincent accepting the award onstage on his behalf.